S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
Log in

NASDAQ:YMAB - Y-mAbs Therapeutics Stock Price, Forecast & News

$31.70
-0.85 (-2.61 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
$30.66
Now: $31.70
$33.41
50-Day Range
$28.04
MA: $30.62
$33.75
52-Week Range
$15.17
Now: $31.70
$34.49
Volume307,337 shs
Average Volume152,566 shs
Market Capitalization$1.26 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.22
Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:YMAB
CUSIPN/A
CIKN/A
Phone646-885-8505

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.11 per share

Profitability

Net Income$-43,270,000.00

Miscellaneous

Employees32
Market Cap$1.26 billion
Next Earnings Date3/27/2020 (Estimated)
OptionableNot Optionable

Receive YMAB News and Ratings via Email

Sign-up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter.


Y-mAbs Therapeutics (NASDAQ:YMAB) Frequently Asked Questions

What is Y-mAbs Therapeutics' stock symbol?

Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB."

How were Y-mAbs Therapeutics' earnings last quarter?

Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) announced its quarterly earnings results on Wednesday, November, 13th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by $0.16. View Y-mAbs Therapeutics' Earnings History.

When is Y-mAbs Therapeutics' next earnings date?

Y-mAbs Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 27th 2020. View Earnings Estimates for Y-mAbs Therapeutics.

What price target have analysts set for YMAB?

4 brokerages have issued 12-month price targets for Y-mAbs Therapeutics' stock. Their forecasts range from $38.00 to $40.00. On average, they expect Y-mAbs Therapeutics' share price to reach $39.33 in the next year. This suggests a possible upside of 24.1% from the stock's current price. View Analyst Price Targets for Y-mAbs Therapeutics.

What is the consensus analysts' recommendation for Y-mAbs Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Y-mAbs Therapeutics.

Has Y-mAbs Therapeutics been receiving favorable news coverage?

News headlines about YMAB stock have trended very positive this week, according to InfoTrie. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Y-mAbs Therapeutics earned a media sentiment score of 3.8 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Y-mAbs Therapeutics.

Are investors shorting Y-mAbs Therapeutics?

Y-mAbs Therapeutics saw a decline in short interest in the month of November. As of November 29th, there was short interest totalling 890,300 shares, a decline of 14.4% from the November 14th total of 1,040,000 shares. Based on an average daily volume of 246,100 shares, the days-to-cover ratio is currently 3.6 days. Currently, 4.6% of the shares of the company are sold short. View Y-mAbs Therapeutics' Current Options Chain.

Who are some of Y-mAbs Therapeutics' key competitors?

What other stocks do shareholders of Y-mAbs Therapeutics own?

Who are Y-mAbs Therapeutics' key executives?

Y-mAbs Therapeutics' management team includes the folowing people:
  • Mr. Thomas Gad, Founder, Chairman, Pres & Head of Bus. Devel. (Age 48)
  • Dr. Claus Juan Møller San Pedro, CEO & Director (Age 56)
  • Mr. Bo Kruse, Exec. VP, Sec., Treasurer, CFO & Director (Age 47)
  • Mr. Joris Wiel Jan Wilms, Sr. VP & COO (Age 44)
  • Dr. Torben Lund-Hansen, Sr. VP & Head of Technical Operations (Age 68)

When did Y-mAbs Therapeutics IPO?

(YMAB) raised $80 million in an initial public offering on Friday, September 21st 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager.

Who are Y-mAbs Therapeutics' major shareholders?

Y-mAbs Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include State Street Corp (0.89%), Millennium Management LLC (0.47%), Alps Advisors Inc. (0.20%), Squarepoint Ops LLC (0.12%), California State Teachers Retirement System (0.08%) and Strs Ohio (0.06%). Company insiders that own Y-mAbs Therapeutics stock include Ashu Tyagi, James Healy, Johan Wedell-Wedellsborg, Moller San Pedro Claus Juan and Thomas Gad. View Institutional Ownership Trends for Y-mAbs Therapeutics.

Which institutional investors are selling Y-mAbs Therapeutics stock?

YMAB stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Alps Advisors Inc. and Barclays PLC. Company insiders that have sold Y-mAbs Therapeutics company stock in the last year include Johan Wedell-Wedellsborg and Thomas Gad. View Insider Buying and Selling for Y-mAbs Therapeutics.

Which institutional investors are buying Y-mAbs Therapeutics stock?

YMAB stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Squarepoint Ops LLC, Strs Ohio, Tuttle Tactical Management, California Public Employees Retirement System, Metropolitan Life Insurance Co NY, Rhumbline Advisers and California State Teachers Retirement System. Company insiders that have bought Y-mAbs Therapeutics stock in the last two years include Ashu Tyagi, James Healy and Moller San Pedro Claus Juan. View Insider Buying and Selling for Y-mAbs Therapeutics.

How do I buy shares of Y-mAbs Therapeutics?

Shares of YMAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Y-mAbs Therapeutics' stock price today?

One share of YMAB stock can currently be purchased for approximately $31.70.

How big of a company is Y-mAbs Therapeutics?

Y-mAbs Therapeutics has a market capitalization of $1.26 billion. The company earns $-43,270,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis. Y-mAbs Therapeutics employs 32 workers across the globe.View Additional Information About Y-mAbs Therapeutics.

What is Y-mAbs Therapeutics' official website?

The official website for Y-mAbs Therapeutics is http://www.ymabs.com/.

How can I contact Y-mAbs Therapeutics?

Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The company can be reached via phone at 646-885-8505 or via email at [email protected]


MarketBeat Community Rating for Y-mAbs Therapeutics (NASDAQ YMAB)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  59 (Vote Outperform)
Underperform Votes:  66 (Vote Underperform)
Total Votes:  125
MarketBeat's community ratings are surveys of what our community members think about Y-mAbs Therapeutics and other stocks. Vote "Outperform" if you believe YMAB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe YMAB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel